Òren Smaletz

4.3k total citations
33 papers, 732 citations indexed

About

Òren Smaletz is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Òren Smaletz has authored 33 papers receiving a total of 732 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Òren Smaletz's work include Prostate Cancer Treatment and Research (20 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Òren Smaletz is often cited by papers focused on Prostate Cancer Treatment and Research (20 papers), Prostate Cancer Diagnosis and Treatment (10 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Òren Smaletz collaborates with scholars based in Brazil, United States and Australia. Òren Smaletz's co-authors include Howard I. Scher, William Kevin Kelly, Kevin Regan, David Verbel, Eric J. Small, Michael W. Kattan, Alex McMillan, Rachel P. Riechelmann, Everardo D. Saad and Frederico Rafael Moreira and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Òren Smaletz

33 papers receiving 721 citations

Peers

Òren Smaletz
Aaron D. Norman United States
Agnes L. F. Chan Taiwan
Christelle Clément-Duchêne France
Patrick J. Medina United States
Pasquale Fiduccia Italy
Louise Stanton United Kingdom
Yon‐Dschun Ko Germany
Sachin Shah United States
Audrey Thomas‐Schoemann France
Felipe Melo Cruz Brazil
Aaron D. Norman United States
Òren Smaletz
Citations per year, relative to Òren Smaletz Òren Smaletz (= 1×) peers Aaron D. Norman

Countries citing papers authored by Òren Smaletz

Since Specialization
Citations

This map shows the geographic impact of Òren Smaletz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Òren Smaletz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Òren Smaletz more than expected).

Fields of papers citing papers by Òren Smaletz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Òren Smaletz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Òren Smaletz. The network helps show where Òren Smaletz may publish in the future.

Co-authorship network of co-authors of Òren Smaletz

This figure shows the co-authorship network connecting the top 25 collaborators of Òren Smaletz. A scholar is included among the top collaborators of Òren Smaletz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Òren Smaletz. Òren Smaletz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Testa, Laura, Max S. Mano, Renata Colombo Bonadio, et al.. (2021). Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. Clinics. 76. e3146–e3146. 3 indexed citations
2.
Maluf, Fernando Cotait, Fabrício Augusto Martinelli de Oliveira, Pedro Emanuel Rubini Liedke, et al.. (2021). Neutropenia Prevention in the Treatment of Post-docetaxel Metastatic, Castration-resistant Prostate Cancer With Cabazitaxel and Prednisone: A Multicenter, Open-label, Single-arm Phase IV Study. Clinical Genitourinary Cancer. 19(3). e171–e177. 1 indexed citations
3.
Smaletz, Òren, Maria Del Pilar Estevez-Diz, Sérgio Jobim Azevedo, et al.. (2021). Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission. International Journal of Gynecological Cancer. 31(4). 562–568. 7 indexed citations
4.
Adra, Nabil, Alexandra Sokolova, Adam Kessel, et al.. (2021). Differential activity of PARP inhibitors in BRCA1- versus BRCA2-altered metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 39(6_suppl). 100–100. 7 indexed citations
5.
Maluf, Fernando Cotait, André P. Fay, Fabio A. Schutz, et al.. (2020). Phase II randomized study of abiraterone acetate plus prednisone (AAP) added to ADT versus apalutamide alone (APA) versus AAP+APA in patients with advanced prostate cancer with noncastrate testosterone levels: (LACOG 0415).. Journal of Clinical Oncology. 38(15_suppl). 5505–5505. 3 indexed citations
6.
7.
Usón, Pedro Luiz Serrano, et al.. (2017). Impact of Pathology Review for Decision Therapy in Localized Prostate Cancer. SHILAP Revista de lepidopterología. 10. 6 indexed citations
8.
9.
Smaletz, Òren, Maria Del Pilar Estevez-Diz, Jorge Sabbaga, et al.. (2015). A phase II trial with anti-Lewis-Y monoclonal antibody (hu3S193) for the treatment of platinum resistant/refractory ovarian, fallopian tube and primary peritoneal carcinoma. Gynecologic Oncology. 138(2). 272–277. 22 indexed citations
10.
Maluf, Fernando Cotait, Òren Smaletz, & Daniel Herchenhorn. (2012). Castration-resistant prostate cancer: systemic therapy in 2012. Clinics. 67(4). 389–394. 25 indexed citations
11.
Smaletz, Òren, et al.. (2012). Long-term benefit (LTB) of sunitinib (SU) treatment for metastatic renal cell carcinoma (mRCC): Retrospective analysis for clinical biomarkers identification.. Journal of Clinical Oncology. 30(5_suppl). 465–465. 1 indexed citations
12.
Smaletz, Òren, Maria Del Pilar Estevez-Diz, Jorge Sabbaga, et al.. (2011). Anti-LeY monoclonal antibody (mAb) hu3S193 (Rebmab 100) in patients with advanced platinum resistant/refractory (PRR) ovarian cancer (OC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC).. Journal of Clinical Oncology. 29(15_suppl). 5078–5078. 3 indexed citations
13.
Smaletz, Òren, et al.. (2006). A oncopsiquiatria no câncer de mama: considerações a respeito de questões do feminino. Archives of Clinical Psychiatry (São Paulo). 33(3). 124–133. 30 indexed citations
14.
Riechelmann, Rachel P., Frederico Rafael Moreira, Òren Smaletz, & Everardo D. Saad. (2005). Potential for drug interactions in hospitalized cancer patients. Cancer Chemotherapy and Pharmacology. 56(3). 286–290. 116 indexed citations
15.
Morris, Michael J., Òren Smaletz, David B. Solit, et al.. (2004). High‐dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer. 100(9). 1868–1875. 30 indexed citations
16.
Nordquist, Luke T., Nicholas Sauter, Michael J. Morris, et al.. (2004). Hormonal induction followed by rapid hormonal cycling for prostate cancer (PC): the MEN's Cycle. Journal of Clinical Oncology. 22(14_suppl). 4609–4609. 1 indexed citations
17.
Smaletz, Òren, Matthew D. Galsky, Howard I. Scher, et al.. (2003). Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration. Annals of Oncology. 14(10). 1518–1524. 50 indexed citations
18.
Verbel, David, William Kevin Kelly, Òren Smaletz, et al.. (2003). Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial. Urology. 61(1). 142–144. 6 indexed citations
19.
Smaletz, Òren & Howard I. Scher. (2002). Outcome predictions for patients with metastatic prostate cancer. 20(2). 155–163. 15 indexed citations
20.
Smaletz, Òren, et al.. (1997). Análise bioquímica e tratamento cirúrgico do empiema pleural parapneumônico em crianças. 7(1). 25–28. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aaron D. Norman Breakdown of academic impact, for papers by Agnes L. F. Chan Breakdown of academic impact, for papers by Christelle Clément-Duchêne Breakdown of academic impact, for papers by Patrick J. Medina Breakdown of academic impact, for papers by Pasquale Fiduccia Breakdown of academic impact, for papers by Louise Stanton Breakdown of academic impact, for papers by Yon‐Dschun Ko Breakdown of academic impact, for papers by Sachin Shah Breakdown of academic impact, for papers by Audrey Thomas‐Schoemann Breakdown of academic impact, for papers by Felipe Melo Cruz
Rankless by CCL
2026